AG-825 | Tyrphostin AG-825 | Selective ErbB2 Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / AG-825

AG-825 {[allProObj[0].p_purity_real_show]}

货号：A276278 同义名： Tyrphostin AG-825

AG-825 是一种选择性、ATP竞争性的ErbB2酪氨酸磷酸化抑制剂，IC50值为0.35 μM。AG-825具有抗癌活性，并显著加速人类中性粒细胞的凋亡。它在克服锰诱导的神经毒性或阿尔茨海默病发展中是一种潜在的活性分子。

AG-825 化学结构
CAS号：149092-50-2

AG-825 3D分子结构
CAS号：149092-50-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

AG-825 纯度/质量文件产品仅供科研

货号：A276278 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

CDK 亚型比较
EGFR 亚型比较

产品名称	Cdc ↓ ↑	CDK1 ↓ ↑	CDK19 ↓ ↑	CDK2 ↓ ↑	CDK3 ↓ ↑	CDK4 ↓ ↑	CDK5 ↓ ↑	CDK6 ↓ ↑	CDK7 ↓ ↑	CDK8 ↓ ↑	CDK9 ↓ ↑	CLK ↓ ↑	其他靶点	纯度
XL413 hydrochloride	++++ Cdc7, IC50: 3.4 nM													{[allProObj[0].p_purity_real_show]}
SU9516		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 22 nM		++ CDK4, IC50: 200 nM								{[allProObj[0].p_purity_real_show]}
RO-3306		+++ CDK1, Ki: 20 nM											ERK,SGK	{[allProObj[0].p_purity_real_show]}
R547		++++ CDK1/CyclinB, Ki: 2 nM		++++ CDK2/CyclinE, Ki: 3 nM		++++ CDK4/CyclinD1, Ki: 1 nM								{[allProObj[0].p_purity_real_show]}
BMS-265246		++++ CDK1/CyclinB, IC50: 6 nM		++++ CDK2/CyclinE, IC50: 9 nM		+ CDK4/CyclinD, IC50: 230 nM								{[allProObj[0].p_purity_real_show]}
NU6027		+ CDK1, Ki: 2.5 μM		+ CDK2, Ki: 1.3 μM									DNA-PK	{[allProObj[0].p_purity_real_show]}
Purvalanol A	++++ Cdc2/CyclinB, IC50: 4 nM			+++ CDK2/CyclinE, IC50: 35 nM CDK2/CyclinA, IC50: 70 nM		+ CDK4/CyclinD1, IC50: 850 nM								{[allProObj[0].p_purity_real_show]}
SCH900776				++ CDK2, IC50: 0.16 μM										{[allProObj[0].p_purity_real_show]}
AUZ 454				++++ CDK2(C118L), Kd: 18.6 nM CDK2(A144C), Kd: 9.7 nM										{[allProObj[0].p_purity_real_show]}
A-674563 HCl				++ CDK2, Ki: 46 nM									PKA	{[allProObj[0].p_purity_real_show]}
JNJ-7706621		++++ CDK1/CyclinB, IC50: 9 nM		++++ CDK2/CyclinE, IC50: 3 nM CDK2/CyclinA, IC50: 4 nM	++ CDK3/CyclinE, IC50: 58 nM	+ CDK4/CyclinD1, IC50: 253 nM		++ CDK6/CyclinD1, IC50: 175 nM						{[allProObj[0].p_purity_real_show]}
AT7519		++ CDK1/CyclinB, IC50: 210 nM		++ CDK2/CyclinA, IC50: 47 nM	+ CDK3/CyclinE, IC50: 360 nM	++ CDK4/CyclinD1, IC50: 100 nM	+++ CDK5/p35, IC50: 13 nM	++ CDK6/CyclinD3, IC50: 170 nM			++++ CDK9/CyclinT, IC50: <10 nM			{[allProObj[0].p_purity_real_show]}
PHA-793887		++ CDK1/CyclinB, IC50: 60 nM		++++ CDK2/CyclinE, IC50: 8 nM CDK2/CyclinA, IC50: 8 nM		++ CDK4/CyclinD1, IC50: 62 nM	++++ CDK5/p25, IC50: 5 nM		++++ CDK7/CyclinH, IC50: 10 nM		++ CDK9/CyclinT1, IC50: 138 nM			{[allProObj[0].p_purity_real_show]}
Milciclib		+ CDK1/CyclinB, IC50: 398 nM		++ CDK2/CyclinE, IC50: 363 nM CDK2/CyclinA, IC50: 45 nM		++ CDK4/CyclinD1, IC50: 160 nM	+ CDK5/p35, IC50: 265 nM		++ CDK7/CyclinH, IC50: 150 nM					{[allProObj[0].p_purity_real_show]}
Kenpaullone		+ CDK1/CyclinB, IC50: 0.4μM		+ CDK2/CyclinE, IC50: 7.5μM CDK2/CyclinA, IC50: 0.68μM			+ CDK5/p35, IC50: 0.85μM							{[allProObj[0].p_purity_real_show]}
SNS-032				+++ CDK2/CyclinE, IC50: 48 nM CDK2/CyclinA, IC50: 38 nM			+ CDK5/p35, IC50: 340 nM		++ CDK7/CyclinH, IC50: 62 nM		++++ CDK9/CyclinT, IC50: 4 nM			{[allProObj[0].p_purity_real_show]}
Dinaciclib		++++ CDK1, IC50: 3 nM		++++ CDK2, IC50: 1 nM			++++ CDK5, IC50: 1 nM				++++ CDK9, IC50: 4 nM			{[allProObj[0].p_purity_real_show]}
PHA-767491 hydrochloride	++++ Cdc7, IC50: 10 nM	+ CDK1, IC50: 250 nM		+ CDK2, IC50: 240 nM			+ CDK5, IC50: 460 nM				+++ CDK9, IC50: 34 nM		MK2	{[allProObj[0].p_purity_real_show]}
(R)-Roscovitine	+ Cdc2/CyclinB, IC50: 0.65 μM			+ CDK2/CyclinE, IC50: 0.7 μM CDK2/CyclinA, IC50: 0.7 μM			++ CDK5/p35, IC50: 0.16 μM							{[allProObj[0].p_purity_real_show]}
Narazaciclib						++++ CDK4/CyclinD1, IC50: 3.87 nM		++++ CDK6/CyclinD1, IC50: 9.82 nM					RET	{[allProObj[0].p_purity_real_show]}
Palbociclib						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						{[allProObj[0].p_purity_real_show]}
Abemaciclib						++++ CDK4, IC50: 2 nM		++++ CDK6, IC50: 10 nM						{[allProObj[0].p_purity_real_show]}
Ribociclib						++++ CDK4, IC50: 10 nM		+++ CDK6, IC50: 39 nM						{[allProObj[0].p_purity_real_show]}
Palbociclib isethionate						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						{[allProObj[0].p_purity_real_show]}
BS-181 HCl									+++ CDK7, IC50: 21 nM					{[allProObj[0].p_purity_real_show]}
(E/Z)-THZ1 dihydrochloride									++++ CDK7, IC50: 3.2 nM					{[allProObj[0].p_purity_real_show]}
LDC4297									++++ CDK7, IC50: 0.13 nM					{[allProObj[0].p_purity_real_show]}
Senexin A			+ CDK19, Kd: 0.31 μM							+ CDK8, Kd: 0.83 μM				{[allProObj[0].p_purity_real_show]}
MSC2530818										++++ CDK8, IC50: 2.6 nM				{[allProObj[0].p_purity_real_show]}
Wogonin											✔			{[allProObj[0].p_purity_real_show]}
Riviciclib HCl		++ CDK1/CyclinB, IC50: 79 nM		+ CDK2/CyclinE, IC50: 2.54 μM CDK2/CyclinA, IC50: 224 nM		++ CDK4/CyclinD1, IC50: 63 nM		+ CDK6/CyclinD3, IC50: 396 nM	+ CDK7/CyclinH, IC50: 2.87 μM		+++ CDK9/CyclinT1, IC50: 20 nM			{[allProObj[0].p_purity_real_show]}
LDC000067				+ CDK2, IC50: 2.441 μM							++ CDK9, IC50: 44 nM			{[allProObj[0].p_purity_real_show]}
Flavopiridol		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 40 nM		+++ CDK4, IC50: 40 nM		+++ CDK6, IC50: 40 nM	+ CDK7, IC50: 300 nM		+++ CDK9, IC50: 20 nM			{[allProObj[0].p_purity_real_show]}
LY2857785									+ CDK7, IC50: 0.246 μM	+++ CDK8, IC50: 0.016 μM	+++ CDK9, IC50: 0.011 μM			{[allProObj[0].p_purity_real_show]}
AZD-5438		+++ CDK1, IC50: 16 nM		++++ CDK2, IC50: 6 nM							+++ CDK9, IC50: 20 nM			{[allProObj[0].p_purity_real_show]}
ML167												++ Dyrk1B , IC50: 1648 nM CLK4, IC50: 136 nM		{[allProObj[0].p_purity_real_show]}
(E/Z)-TG003												+++ mCLK1, IC50: 200 nM mCLK4, IC50: 15 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750/T790M), IC50: 14 nM EGFR (E746_A750), IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Daphnetin	+ EGFR, IC50: 7.67 μM					PKA,PKC	{[allProObj[0].p_purity_real_show]}
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		{[allProObj[0].p_purity_real_show]}
PD168393	++++ EGFR, IC50: 0.70 nM						{[allProObj[0].p_purity_real_show]}
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		{[allProObj[0].p_purity_real_show]}
Norcantharidin	✔						{[allProObj[0].p_purity_real_show]}
CL-387785	++++ EGFR, IC50: 370 pM						{[allProObj[0].p_purity_real_show]}
WHI-P154	+++ EGFR, IC50: 4 nM					VEGFR,Src	{[allProObj[0].p_purity_real_show]}
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	{[allProObj[0].p_purity_real_show]}
AG 555	+ EGFR, IC50: 0.7 μM						{[allProObj[0].p_purity_real_show]}
AG 494	+ EGFR, IC50: 1.2 μM						{[allProObj[0].p_purity_real_show]}
AG-556	+ EGFR, IC50: 5 μM						{[allProObj[0].p_purity_real_show]}
RG13022	+ EGFR, IC50: 4 μM						{[allProObj[0].p_purity_real_show]}
Tyrphostin RG 14620	✔						{[allProObj[0].p_purity_real_show]}
Vandetanib	+ EGFR, IC50: 500 nM						{[allProObj[0].p_purity_real_show]}
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		{[allProObj[0].p_purity_real_show]}
AZD3759	++++ EGFR (WT), IC50: 0.3 nM EGFR (L858R), IC50: 0.2 nM						{[allProObj[0].p_purity_real_show]}
Erlotinib	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Saracatinib	+++ EGFR, IC50: 5 nM EGFR (L861Q), IC50: 4 nM						{[allProObj[0].p_purity_real_show]}
AG1557	✔						{[allProObj[0].p_purity_real_show]}
Rociletinib	++ EGFR (L858R/T790M), Ki: 21.5 nM EGFR (wt), Ki: 303.3 nM						{[allProObj[0].p_purity_real_show]}
AG490	+ EGFR, IC50: 0.1 μM						{[allProObj[0].p_purity_real_show]}
Cetuximab	++++ EGFR, Kd: 0.39 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib	++ L858R/T790M EGFR, IC50: 11.44 nM WT EGFR, IC50: 12.92 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Chrysophanol	✔					mTOR	{[allProObj[0].p_purity_real_show]}
PD153035	++++ EGFR, Ki: 5.2 pM						{[allProObj[0].p_purity_real_show]}
Olmutinib	✔					BTK	{[allProObj[0].p_purity_real_show]}
WZ4002	++++ EGFR (L858R/T790M), IC50: 8 nM EGFR (L858R), IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Icotinib	+++ EGFR, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Cyasterone	✔						{[allProObj[0].p_purity_real_show]}
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						{[allProObj[0].p_purity_real_show]}
WZ8040	✔						{[allProObj[0].p_purity_real_show]}
(-)-Epigallocatechin Gallate	✔						{[allProObj[0].p_purity_real_show]}
AG 18	+ EGFR, IC50: 35 μM						{[allProObj[0].p_purity_real_show]}
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						{[allProObj[0].p_purity_real_show]}
Falnidamol	✔						{[allProObj[0].p_purity_real_show]}
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	{[allProObj[0].p_purity_real_show]}
Butein	✔						{[allProObj[0].p_purity_real_show]}
Genistein	✔						{[allProObj[0].p_purity_real_show]}
SU5214	+ EGFR, IC50: 36.7 μM						{[allProObj[0].p_purity_real_show]}
Naquotinib	✔						{[allProObj[0].p_purity_real_show]}
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		{[allProObj[0].p_purity_real_show]}
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		{[allProObj[0].p_purity_real_show]}
Lazertinib	++++ L858R/T790M EGFR, IC50: 2 nM WT EGFR, IC50: 76 nM				++++ Del19/T790M, IC50: 1.7 nM		{[allProObj[0].p_purity_real_show]}
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						{[allProObj[0].p_purity_real_show]}
MTX-211	✔					PI3K	{[allProObj[0].p_purity_real_show]}
(E)-AG 99	✔						{[allProObj[0].p_purity_real_show]}
Licochalcone D	✔					PARP,Caspase	{[allProObj[0].p_purity_real_show]}
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM		{[allProObj[0].p_purity_real_show]}
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		{[allProObj[0].p_purity_real_show]}
Firmonertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Tyrphostin AG30	✔						{[allProObj[0].p_purity_real_show]}
EGFR-IN-12	++ EGFR, IC50: 21 nM						{[allProObj[0].p_purity_real_show]}
Mobocertinib	✔						{[allProObj[0].p_purity_real_show]}
(Rac)-JBJ-04-125-02	✔						{[allProObj[0].p_purity_real_show]}
(S)-Sunvozertinib	✔						{[allProObj[0].p_purity_real_show]}
BLU-945	✔						{[allProObj[0].p_purity_real_show]}
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			{[allProObj[0].p_purity_real_show]}
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			{[allProObj[0].p_purity_real_show]}
ARRY-380 analog				✔			{[allProObj[0].p_purity_real_show]}
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			{[allProObj[0].p_purity_real_show]}
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			{[allProObj[0].p_purity_real_show]}
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			{[allProObj[0].p_purity_real_show]}
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			{[allProObj[0].p_purity_real_show]}
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			{[allProObj[0].p_purity_real_show]}
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms	{[allProObj[0].p_purity_real_show]}
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^T790M, IC50: 0.79 nM EGFR^L858R/T790M, IC50: 0.51 nM		{[allProObj[0].p_purity_real_show]}
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	{[allProObj[0].p_purity_real_show]}
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			{[allProObj[0].p_purity_real_show]}
Tucatinib				+++ ErbB2, IC50: 8 nM			{[allProObj[0].p_purity_real_show]}
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Raf,Src	{[allProObj[0].p_purity_real_show]}
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			{[allProObj[0].p_purity_real_show]}
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	{[allProObj[0].p_purity_real_show]}
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			{[allProObj[0].p_purity_real_show]}
Afatinib dimaleate	++++ EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM			++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Canertinib dihydrochloride	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			{[allProObj[0].p_purity_real_show]}
Allitinib tosylate	++++ EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			{[allProObj[0].p_purity_real_show]}
Afatinib	++++ EGFR (L858R), IC50: 10 nM EGFR (wt), IC50: 0.5 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			{[allProObj[0].p_purity_real_show]}
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			{[allProObj[0].p_purity_real_show]}
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			{[allProObj[0].p_purity_real_show]}
ALK-IN-1					++ EGFR(C797S/del19), IC50: 138.6 nM EGFR(del19), IC50: 36.8 nM	ALK	{[allProObj[0].p_purity_real_show]}
Brigatinib					+ EGFR(del19), IC50: 39.9 nM EGFR(C797S/T790M/del19), IC50: 67.2 nM	ALK,FLT3	{[allProObj[0].p_purity_real_show]}
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	{[allProObj[0].p_purity_real_show]}
EAI045					✔		{[allProObj[0].p_purity_real_show]}
Almonertinib					✔		{[allProObj[0].p_purity_real_show]}
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		{[allProObj[0].p_purity_real_show]}
EGFR-IN-7					++++ EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM EGFR^L858R/T790M, IC50: 0.19 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

AG-825 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.58mL

2.52mL

1.26mL

25.16mL

5.03mL

2.52mL

AG-825 技术信息

CAS号	149092-50-2
分子式	C₁₉H₁₅N₃O₃S₂
分子量	397.471

别名	Tyrphostin AG-825
运输	蓝冰

存储条件

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 250 mg/mL(628.98 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

AG-825 {[allProObj[0].p_purity_real_show]}

AG-825 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

AG-825 质控信息

AG-825 实验方案

AG-825 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

AG-825 {[allProObj[0].p_purity_real_show]}

AG-825 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

AG-825 质控信息

AG-825 实验方案

AG-825 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

AG-825 纯度/质量文件产品仅供科研